Observational Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. May 15, 2019; 11(5): 424-435
Published online May 15, 2019. doi: 10.4251/wjgo.v11.i5.424
Table 3 Prognostic factors for patients with hepatocellular carcinoma receiving sorafenib treatment
Univariate analysisHR (95%CI)P value
Age (per 1 yr increase)1.16 (1.032-1.304)0.0127
Sex (male vs female)0.062 (0.000382-1.008)0.0561
Viral hepatitis (presence vs absence)1.416(0.405-4.95)0.5862
Albumin (per 1 g/dL decrease)0.427 (0.0750-2.44)0.3388
Prothrombin time (per 1% decrease)1.008 (0.969-1.048)0.3910
Total bilirubin (per 1 mg/dL increase)4.203 (0.417-42.30)0.2230
Platelet count (per 104/µL decrease)0.906 (0.807-1.018)0.4970
AFP (per 1 ng/mL increase)1.000 (1.000-1.00)0.3334
DCP (per 1 mAU/mL increase)1.000 (1.000-1.00)0.0136
AFP-L3% (per 1% increase)0.999 (0.969-1.031)0.9484
VEGF (per 1 pg/mL increase)0.982 (0.952-1.01)0.2426
VEGFR-2 (per 1 pg/mL increase)1.00 (0.999-1.000)0.8947
Maximum tumor size (per 1 cm increase)1.026 (0.868-1.214)0.7622
Tumor number (per 1 increase)0.751 (0.5-1.129)0.1690
PVTT (presence vs absence)0.347 (0.0384-3.141)0.3464
Distant metastasis (presence vs absence)0.489 (0.129-1.854)0.2936
ADAMTS13:AC (per 1% increase)0.936 (0.895-0.978)0.0035
VWF:Ag (per 1% increase)0.996 (0.991-1.000)0.9227
VWF:Ag/ADAMTS13:AC (per 1 increase)1.33 (0.998-1.772)0.0520
Multivariate analysis
ADAMTS13:AC (per 1% increase)0.937 (0.895-0.980)0.0045
HCC: Hepatocellular carcinoma; AFP: Alpha fetoprotein; DCP: Des-γ-carboxy prothrombin; AFP-L3%: Lens culinaris agglutinin-reactive alpha-fetoprotein; VEGF: Vascular endothelial growth factor; VEGFR-2: VEGF receptor-2; PVTT: Portal vein tumor thrombosis; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; HR: Hazard ratio; CI: Confidence interval.